Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:183:49-89.
doi: 10.1007/978-3-030-96376-7_2.

Melanoma: An immunotherapy journey from bench to bedside

Vishal Navani  1 , Moira C Graves  2 , Hiren Mandaliya  3 , Martin Hong  3 , Andre van der Westhuizen  2   3 , Jennifer Martin  2   4 , Nikola A Bowden  2
Affiliations

Melanoma: An immunotherapy journey from bench to bedside

Vishal Navani et al. Cancer Treat Res. 2022.

Abstract

Melanoma gave science a window into the role immune evasion plays in the development of malignancy. The entire spectrum of immune focused anti-cancer therapies has been subjected to clinical trials in this disease, with limited success until the immune checkpoint blockade era. That revolution launched first in melanoma, heralded a landscape change throughout cancer that continues to reverberate today.

Keywords: CTLA-4; Immune checkpoint; Immunotherapy; Immunotherapy resistance; Immunotherapy response; Melanoma; PD-1; PD-L1.

PubMed Disclaimer

References

    1. Printz C (2001) Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst 93(14):1047–1048 - PubMed - DOI
    1. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303–1310 - PubMed - DOI
    1. Keung EZ, Gershenwald JE (2018) The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 18(8):775–84
    1. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306 - PubMed - DOI
    1. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 23(10):2346–2357 - DOI

LinkOut - more resources